Goossens, G.H. (Gijs H.)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
6 results
Search Results
Now showing 1 - 6 of 6
- OBEDIS core variables project: European expert guidelines on a minimal core set of variables to include in randomized, controlled clinical trials of obesity interventions(Karger, 2020) Yki-Järvinen, H. (Hannele); Farpour-Lambert, N. (Nathalie); Sadaf-Farooqi, I. (I.); Natali, A. (Andrea); Roche, H. (Helen); Alligier, M. (Maud); Boirie, Y. (Yves); Ziegler, O. (Olivier); Jacobi, D. (David); Sørensen, T.I.A (Thorkild I. A.); Tappy, L. (Luc); Scheen, A.J. (André J.); Palmeira, A.L. (Antonio L.); Frühbeck, G. (Gema); Halford, J.C.G. (Jason C. G.); Brunault, P. (Paul); Bouwman, J. (Jildau); Barrès, R. (Romain); Langin, D. (D.); Julia, C. (Chantal); Clement, K. (K.); Blaak, E.E. (Ellen E.); Pagotto, U. (Uberto); Simon, C. (Chantal); Hager, J. (Jörg); Hauner, H. (Hans); Goossens, G.H. (Gijs H.); Oppert, J.M. (Jean M.); Laville, M. (Martine); Campbell, K. (Kristina); Neovius, M. (Martin); Rydén, M. (Mikael)Heterogeneity of interindividual and intraindividual responses to interventions is often observed in randomized, controlled trials for obesity. To address the global epidemic of obesity and move toward more personalized treatment regimens, the global research community must come together to identify factors that may drive these heterogeneous responses to interventions. This project, called OBEDIS (OBEsity Diverse Interventions Sharing – focusing on dietary and other interventions), provides a set of European guidelines for a minimal set of variables to include in future clinical trials on obesity, regardless of the specific endpoints. Broad adoption of these guidelines will enable researchers to harmonize and merge data from multiple intervention studies, allowing stratification of patients according to precise phenotyping criteria which are measured using standardized methods. In this way, studies across Europe may be pooled for better prediction of individuals’ responses to an intervention for obesity – ultimately leading to better patient care and improved obesity outcomes.
- Obesity and COVID-19: A perspective from the european association for the study of obesity on immunological perturbations, therapeutic challenges, and opportunities in obesity(Karger, 2020) Farpour-Lambert, N. (Nathalie); Woodward, E. (Euan); Holm, J.C. (Jens-Christian); Mullerova, D. (Dana); Frühbeck, G. (Gema); Dicker, D. (Dror); Goossens, G.H. (Gijs H.)Accumulating evidence suggests that obesity is a major risk factor for the initiation, progression, and outcomes of coronavirus disease 2019 (COVID-19). The European Association for the Study of Obesity (EASO), as a scientific and medical society dedicated to the promotion of health and well-being, is greatly concerned about the concomitant obesity and COVID-19 pandemics and their impact on health and society at large. In this perspective, we will address the inherent immunological perturbations and alterations in the renin-angiotensin-aldosterone system in patients with obesity and COVID-19, and discuss how these impairments may underlie the increased susceptibility and more detrimental outcomes of COVID-19 in people with obesity. Clearly, this has important implications for preventive measures, vaccination, and future therapeutic strategies to combat COVID-19. Furthermore, we will highlight important knowledge gaps and provide suggestions for future research and recommendations for policy actions. Since many new reports on COVID-19 rapidly appear, the present perspective should be seen as a focus for discussion to drive forward further understanding, research initiatives, and clinical management of COVID-19.
- Obesity and COVID-19: The two sides of the coin(Karger, 2020) Farpour-Lambert, N. (Nathalie); Busetto, L. (Luca); Ramos-Salas, X. (Ximena); OMalley, G. (Grace); Woodward, E. (Euan); Mullerova, D. (Dana); Hassapiou, M.N. (Maria N.); Frühbeck, G. (Gema); Yumuk, V. (Volkan); Halford, J.C.G. (Jason C. G.); Golan, R. (Rachel); Sagen, J.V. (Jorn V.); Bettini, S. (Silvia); Dicker, D. (Dror); Goossens, G.H. (Gijs H.)The World Health Organization declared COVID-19, the infectious disease caused by the coronavirus SARS-CoV-2, a pandemic on March 12, 2020. COVID-19 is causing massive health problems and economic suffering around the world. The European Association for the Study of Obesity (EASO) promptly recognised the impact that the outbreak could have on people with obesity. On one side, emerging data suggest that obesity represents a risk factor for a more serious and complicated course of COVID-19 in adults. On the other side, the health emergency caused by the outbreak diverts attention from the prevention and care of non-communicable chronic diseases to communicable diseases. This might be particularly true for obesity, a chronic and relapsing disease frequently neglected and linked to significant bias and stigmatization. The Obesity Management Task Force (OMTF) of EASO contributes in this paper to highlighting the key aspects of these two sides of the coin and suggests some specific actions.
- European association for the study of obesity position statement on the global COVID-19 pandemic(Karger, 2020) Farpour-Lambert, N. (Nathalie); Busetto, L. (Luca); Ramos-Salas, X. (Ximena); Woodward, E. (Euan); Holm, J.C. (Jens-Christian); Lehtinen-Jacks, S. (Susanna); Mullerova, D. (Dana); Frühbeck, G. (Gema); Yumuk, V. (Volkan); Halford, J.C.G. (Jason C. G.); O’Malley, G. (Grace); Handjieva-Darlenska, T. (Teodora); Rutter, H. (Harry); Sagen, J.V. (Jorn V.); Dicker, D. (Dror); Hassapidou, M. (Maria); Lyn-Baker, J. (Jennifer); Goossens, G.H. (Gijs H.)COVID-19, the infectious disease caused by the coronavirus SARS-CoV-2, was declared a pandemic by the World Health Organization on March 12, 2020. The European Association for the Study of Obesity (EASO), as a scientific and medical society dedicated to the promotion of health and well-being, is greatly concerned about this global health challenge and its significant impacts on individuals, families, communities, health systems, nations, and wider society.
- The ABCD of obesity: An EASO position statement on a diagnostic term with clinical and scientific implications(S. Karger AG, 2019) Farpour-Lambert, N. (Nathalie); Busetto, L. (Luca); Woodward, E. (Euan); Frühbeck, G. (Gema); Yumuk, V. (Volkan); Halford, J.C.G. (Jason C. G.); Hebebrand, J. (Joahnnes); Blaak, E.E. (Ellen E.); Toplak, H. (Hermann); Dicker, D. (Dror); Goossens, G.H. (Gijs H.)Obesity is a frequent, serious, complex, relapsing, and chronic disease process that represents a major public health problem. The coining of obesity as an adiposity-based chronic disease (ABCD) is of particular relevance being in line with EASO’s proposal to improve the International Classification of Diseases ICD-11 diagnostic criteria for obesity based on three dimensions, namely etiology, degree of adiposity, and health risks. The body mass index as a unique measurement of obesity does not reflect the whole complexity of the disease. Obesity complications are mainly determined by 2 pathological processes, i.e., physical forces (fat mass disease) as well as endocrine and immune responses (sick fat disease), which are embedded in a cultural and physical context leading to a specific ABCD stage.
- Vaccinating people with obesity for COVID-19: EASO call for action(Karger, 2021) Dicker, D. (Dror); Golan, R. (Rachel); Lyn-Baker, J. (Jennifer); Busetto, L. (Luca); Frühbeck, G. (Gema); Goossens, G.H. (Gijs H.); Halford, J.C.G. (Jason C. G.); Holm, J.C. (Jens-Christian); Woodward, E. (Euan); Farpour-Lambert, N. (Nathalie)